GlassScriptPhysician profile
Sida Niu
NPI 1699201905
$3,606.79
in general payments reported to CMS, 2019-2025
31 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.17 · 2021: $73.98 · 2022: $728 · 2023: $672 · 2024: $947 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,751 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,750.83 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,001.73 | 2023-2025 | Orgovyx, Gemtesa, Myfembree |
| Astellas Pharma US INC | $359.06 | 2022-2023 | Myrbetriq |
| Procept Biorobotics Corporation | $262.45 | 2022-2025 | |
| Janssen Biotech, INC. | $190.91 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Boston Scientific Corporation | $190.73 | 2023-2025 | Advance Xp, General - Erectile Dysfunction, Rezum Generator |
| Palette Life Sciences, INC. | $184.00 | 2022 | |
| Calyxo, INC. | $181.05 | 2025 | Cvac Aspiration System |
| Axonics, INC. | $149.91 | 2023 | Axonics |
| Intuitive Surgical, INC. | $149.80 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $122.97 | 2021-2025 | Provenge |
| Verity Pharmaceuticals INC. | $120.57 | 2023-2024 | Trelstar |
| Merck Sharp & Dohme LLC | $120.20 | 2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $87.98 | 2023-2025 | |
| Urogen Pharma, INC. | $60.24 | 2025 | |
| Medtronic, INC. | $46.63 | 2024-2025 | Interstim |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $45.80 | 2025 | Eligard, Jatenzo |
| Amgen INC. | $38.65 | 2022-2023 | Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $38.10 | 2023-2024 | |
| Bluewind Medical | $36.71 | 2024 | Revi |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Abbvie INC. | $33.36 | 2023-2024 | |
| Olympus America INC. | $21.94 | 2024 | Itind System |
| Travere Therapeutics, INC. | $21.70 | 2021 | |
| Accord Healthcare, INC. | $20.75 | 2025 | |
| Cure Medical LLC | $19.17 | 2020 | |
| Antares Pharma, INC. | $17.63 | 2024 | Xyosted |
| Progenics Pharmaceuticals, INC. | $17.55 | 2024 | |
| Pfizer INC. | $16.41 | 2022 | |
| Cook Medical LLC | $15.73 | 2025 | Resonance |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sida Niu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.